Now, researchers at the University of Michigan Comprehensive Cancer Center are reporting success with a new method of attacking these cancerous tumors. Radiation is aimed precisely at the tumor - not the entire liver - and 400 times the normal amount of chemotherapy is fed directly to the liver. The combination delivers an intensive punch directly to the tumors while limiting exposure to normal tissue.

Of the 128 patients treated, median survival was 15.8 months, significantly longer than traditional survival rates for patients with these types of tumors. Results of the study appear in the Dec. 1 issue of the Journal of Clinical Oncology.

The researchers looked specifically at patients with bile duct cancer, liver cancer or colon cancer that had spread to the liver, all of whom were not candidates for surgery. Typical survival rates for these cancers are eight or nine months. In this study, liver cancer patients lived an average 15.2 months, bile duct cancer patients lived 13.3 months and colon cancer patients lived 17.2 months.

"The patients with metastatic colorectal cancer who were entered in this trial, for example, were for the most part out of chemotherapy options at the time of referral. These are patients that we estimate would have had a life expectancy of nine, maybe 12 months. They also did not have any surgical or other local treatment options. So a median survival of 17 months in such patients is quite a substantial improvement and definitely clinically relevant," says lead study author Edgar Ben-Josef, M.D., associate professor of radiation oncology at the U-M Medical School.

In the study, patients received radiation twice daily for two weeks, along with a continuous infusion of the chemotherapy drug
'"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
28-Nov-2005